目的 探討復(fù)方黃柏液聯(lián)合巴柳氮鈉治療潰瘍性直腸炎的臨床療效。方法 選取2019年5月-2021年9月在鄭州市第一人民醫(yī)院肛腸外科治療的潰瘍性直腸炎患者70例,隨機(jī)分為對照組和治療組,每組各35例。對照組口服巴柳氮鈉膠囊,5粒/次,3次/d。治療組在對照組的基礎(chǔ)上,外用復(fù)方黃柏液,100 mL藥液加溫開水100 mL,其藥液溫度38℃左右,將調(diào)好的藥液用器具灌入直腸內(nèi),2次/d。兩組均連續(xù)治療15 d。觀察兩組的臨床療效及癥狀緩解情況,比較兩組治療前后的改良梅奧(Mayo)評分及白細(xì)胞介素-6(IL-6)、腫瘤壞死因子-α(TNF-α)、C-反應(yīng)蛋白(CRP)、白細(xì)胞介素-8(IL-8)血清水平和不良反應(yīng)。結(jié)果 治療后,治療組的臨床有效率明顯高于對照組(97.14% vs 77.14%,P<0.05)。治療后,治療組患者貧血、腹瀉、黏液膿血便、腹痛癥狀緩解時(shí)間均明顯短于對照組(P<0.05)。治療后,兩組患者IL-6、IL-8、TNF-α、CRP水平明顯下降(P<0.05),且治療組治療后的IL-6、IL-8、TNF-α、CRP水平均明顯低于對照組(P<0.05)。治療后,兩組改良Mayo評分顯著下降(P<0.05),且治療組患者治療后的改良Mayo評分明顯低于對照組(P<0.05)。結(jié)論 復(fù)方黃柏液聯(lián)合巴柳氮鈉治療潰瘍性直腸炎效果確切,癥狀緩解明顯,能有效降低機(jī)體炎癥反應(yīng),且安全有效,值得臨床推廣借鑒。

Objective To investigate the clinical efficacy of Compound Huangbai Liquid combined with balsalazide disodium in treatment of ulcerative proctitis.Methods Patients (70 cases) with ulcerative proctitis in Zhengzhou First People’s Hospital from May 2019 to September 2021 were divided into control and treatment groups, and each group had 35 cases. Patients in the control group were po administered with Balsalazide Sodium Capsules, 5 grains/time, three times daily. Patients in the treatment group were external administered with Compound Huangbai Liquid on the basis of the control group, 100 mL added into warm water 100 mL. Its liquid temperature is about 38 ℃, and it is irrigated into the rectum by an instrument, twice daily. Patients in two groups were treated for 15 d. After treatment, the clinical evaluation and the improvement of clinical symptoms were evaluated, and the modified Mayo score, interleukin-6 (IL-6), C-reactive protein (CRP), and tumor necrosis factor-α (TNF-α), interleukin-8 (IL-8) and adverse reactions in two groups before and after treatment were compared.Results After treatment, the clinical effective rates of the treatment group was better than that in the control group (97.14% vs 77.14%, P < 0.05). After treatment, the improvement time of diarrhea, abdominal pain, anemia, mucus, pus and blood in the treatment group was significantly earlier than that in the control group (P < 0.05). After treatment, the levels of IL-6, IL-8, TNF-α, and CRP in two groups were significantly decreased (P < 0.05), and the decrease was more obvious in the treatment group (P < 0.05). After treatment, the modified Mayo scores in two groups were significantly decreased (P < 0.05), and the decrease was more obvious in the treatment group (P < 0.05).Conclusion Compound Huangbai Liquid combined with balsalazide disodium in treatment of ulcerative proctitis has a definite therapeutic effect, with obvious symptom relief, can effectively reduce the body’s inflammatory response, is safe and effective, and is worthy of clinical promotion.

R975

河南省醫(yī)學(xué)科技攻關(guān)計(jì)劃項(xiàng)目(182102311146)